Digital therapists can help people with IBS.

Published Date: 02 Mar 2023

Although further research is needed, these tools may improve clinical management.

Read Full News

Latest News

Family History of Kidney Failure Tied to CKD Progression

In patients with chronic kidney disease, a family history of kidney failure may raise the risk for disease progression, even after accounting for individual genetic risk and social factors.

AI Finds Three Predictive Variants for Postoperative Sepsis

A genome-wide AI model prioritizes three genetic variants linked to postoperative sepsis and outlines how preoperative genotyping could support targeted monitoring strategies.

Are Italian Doctors Being Punished for Compassion?

The case of six Italian physicians accused of falsifying detention fitness certificates has ignited debate over science, conscience, and politics.

Managing Resistant Hypertension Is Like Playing Chess

Managing resistant hypertension requires looking two moves ahead. Dr Chuck Vega discusses edema, hypokalemia, and the surprising renal benefits of MRAs.

EU Panel Supports New Pediatric EoE Treatment

The CHMP has recommended approval of Jorveza oral suspension 0.2 mg/mL, the first licensed pediatric formulation of budesonide for eosinophilic esophagitis in the EU.

Does Budesonide Shield Against Air Pollution in Rhinitis?

In patients with allergic rhinitis, intranasal budesonide lowers type 2 and neutrophilic marker levels, improves airflow, and alters epigenetic age signals after allergen or diesel exhaust exposure.

Todays Updates

Adjuvant Belzutifan Combo Is ‘Practice Changing’ in RCC

Adding belzutifan to standard adjuvant pembrolizumab cut the risk for recurrence or death in patients with resected clear cell renal cell carcinoma.

Todays Updates

Adjuvant Belzutifan Combo Is ‘Practice Changing’ in RCC

Adding belzutifan to standard adjuvant pembrolizumab cut the risk for recurrence or death in patients with resected clear cell renal cell carcinoma.

Latest News

In patients with chronic kidney disease, a family history of kidney failure may raise the risk for disease progression, even after accounting for individual genetic risk and social factors.

A genome-wide AI model prioritizes three genetic variants linked to postoperative sepsis and outlines how preoperative genotyping could support targeted monitoring strategies.

The case of six Italian physicians accused of falsifying detention fitness certificates has ignited debate over science, conscience, and politics.

Managing resistant hypertension requires looking two moves ahead. Dr Chuck Vega discusses edema, hypokalemia, and the surprising renal benefits of MRAs.

The CHMP has recommended approval of Jorveza oral suspension 0.2 mg/mL, the first licensed pediatric formulation of budesonide for eosinophilic esophagitis in the EU.

In patients with allergic rhinitis, intranasal budesonide lowers type 2 and neutrophilic marker levels, improves airflow, and alters epigenetic age signals after allergen or diesel exhaust exposure.

News All Time

Vascular Cognitive Impairment and Dementia

This state of the art review describes the clinical features, pathophysiology, and biomarkers of vascular cognitive impairment and dementia for cardiovascular clinicians.

Impact of Environmental Allergens on Asthma Varies With Age

Older adults may be more vulnerable to asthma, study suggests.

Lymphoma Tx Linked to Mild Photodistributed Skin Reactions

About 1 in 5 patients with B-cell lymphoma treated with loncastuximab develop skin-related adverse events, particularly photodistributed erythematous patches, a study finds.

EMA Supports First European Therapy for WHIM Syndrome

WHIM syndrome is an ultra-rare hereditary immunodeficiency disease that leads to recurrent severe infections and an increased risk for viral-associated cancer.

Study Backs Longer Compounded Lido Plus Epi Shelf Life

Research supports the safety and efficacy of compounded lidocaine plus epinephrine for up to 24 hours at room temperature and up to 7 days with refrigeration.

Two New Options for Chronic Spontaneous Urticaria in the EU

EU advisers recommend an oral add-on for adults who remain symptomatic on antihistamines and expanded dupilumab to ages 2-11, bringing the first biologic option to this group.

Secukinumab Doubles Remission Rate in Polymyalgia Rheumatica

The REPLENISH trial finds secukinumab doubles the remission rate and significantly lowers steroid use in relapsing polymyalgia rheumatica.

Store Peanut Products Effective for Desensitization in Kids?

A practical volume-based peanut oral immunotherapy protocol using store-bought peanut powder appears effective and safe for desensitizing children with peanut allergy.

Walk-In Visits Cut Wait Times for Children With AD, HS

Walk-in appointments can reduce the time to pediatric dermatology visits for both atopic dermatitis and hidradenitis suppurativa and reduce ED visits for atopic dermatitis, a study finds.

Measles Cases in South Carolina Rise by 6 to 979

Measles cases in South Carolina surged to 979 on Tuesday, state health data ⁠showed, including six additional infections since Friday.

Severe Infection Linked to Long-term IBD Risk

Severe infections requiring hospitalization are associated with a markedly increased long-term IBD risk, with immune-related genetic variants modifying susceptibility.

Study Reveals Gaps in ED Syphilis Screening

Despite increased STI testing in US emergency departments from 2020 to 2024, syphilis screening is often missed, particularly among female and insured patients.

Company Files for Approval of New Pustular Psoriasis Rx

Imsidolimab is a monoclonal antibody that inhibits interleukin-36 receptor signaling and is administered intravenously.

Molluscum Rx: Recommendations From a Pediatric Dermatologist

Dr Swanson tells families that almost all kids get poxvirus-caused bumps and while treatment isn’t mandatory, options include topical cantharidin, berdazimer gel, and intralesional candida injections.

RSV Tamps Down Rhinovirus Coinfection in Infants

Order of infection appeared to affect disease severity in nasal tissue models.

Earlier Mepolizumab in EGPA May Raise Remission Rate

Initiating mepolizumab within 3 months of EGPA diagnosis is associated with a higher remission rate, earlier glucocorticoid withdrawal, and less damage accrual.